ACM
TEVA icon

Atika Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Atika Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,000
Closed -$9.36M – 91
2025
Q4 		$9.36M Buy
+3,000
New +$73.9K 0.99% 31

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atika Capital Management's TEVA Position: Q1 2026 in Review

Atika Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 33% in Q1 2026, selling an estimated $7.72M and leaving 477,000 shares worth $14.4M. The position accounts for 1.8% of the portfolio, ranked #16.

Atika Capital Management first reported a position in TEVA in Q1 2015 and has held it in 5 quarters since. The position peaked at $22.4M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Atika Capital Management held 477,000 shares of Teva Pharmaceuticals worth $14.4M as of Q1 2026.
  • Atika Capital Management sold 240,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $7.72M.
  • Teva Pharmaceuticals made up 1.8% of Atika Capital Management's portfolio in Q1 2026, its #16 holding.
  • Atika Capital Management first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 5 quarters since.
  • Atika Capital Management's Teva Pharmaceuticals position peaked at $22.4M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.